Mechanism of action
Fluvoxamine selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane by blocking the serotonin transporter (SERT). This increases synaptic serotonin availability in the central nervous system, particularly in areas regulating mood and anxiety.
Unique pharmacologic properties distinguish fluvoxamine from other SSRIs. It acts as a potent agonist at sigma-1 receptors, which may contribute to its anti-inflammatory effects and potential neuroprotective properties. Sigma-1 receptor activity modulates endoplasmic reticulum stress responses and may explain emerging interest in fluvoxamine for conditions beyond psychiatry.
Fluvoxamine has minimal affinity for other neurotransmitter receptors including muscarinic, histaminergic (H1), and adrenergic receptors, resulting in fewer anticholinergic and sedative side effects compared to tricyclic antidepressants. However, the serotonergic mechanism still carries risk for serotonin syndrome when combined with other serotonergic agents.
- Fluvoxamine is the only SSRI that is a potent sigma-1 receptor agonist, contributing to anti-inflammatory properties.
- Most potent CYP1A2 inhibitor among SSRIs; contraindicated with tizanidine, alosetron, and pimozide.
- Fluvoxamine has minimal effect on CYP2D6, unlike fluoxetine and paroxetine which are strong CYP2D6 inhibitors.
- FDA-approved for OCD in children aged 8 years and older; first-line pharmacologic option for pediatric OCD.
- Increased risk of suicidal ideation in patients under 24 years; requires black box warning and close monitoring.
- Concomitant use with MAOIs is contraindicated due to serotonin syndrome risk; requires 14-day washout period.
- Nausea and somnolence are the most common adverse effects, often limiting tolerability compared to other SSRIs.
- Smoking induces CYP1A2, potentially lowering fluvoxamine levels; higher doses may be needed in smokers.
- Risk of serotonin syndrome increases with tramadol, triptans, linezolid, or other serotonergic agents.
Indications
FDA-approved indications:
- Obsessive-compulsive disorder (OCD) — approved for adults and children aged 8 years and older; fluvoxamine is considered a first-line pharmacologic treatment for OCD
- Social anxiety disorder (social phobia) — approved for adults using the extended-release formulation
Off-label uses:
- Major depressive disorder
- Panic disorder
- Post-traumatic stress disorder (PTSD)
- Generalized anxiety disorder
- Eating disorders (particularly bulimia nervosa)
Fluvoxamine is less commonly prescribed than other SSRIs such as fluoxetine or sertraline, primarily due to its adverse effect profile (particularly nausea and somnolence) and significant drug interaction potential. However, it remains an important option for treatment-resistant OCD and in patients who have not responded to other SSRIs.
Pharmacokinetics
Absorption: Fluvoxamine is well absorbed after oral administration with bioavailability of approximately 53% due to first-pass metabolism. Peak plasma concentrations occur within 3 to 8 hours. Food does not significantly affect absorption.
Distribution: The volume of distribution is large, approximately 25 L/kg, indicating extensive tissue distribution. Plasma protein binding is approximately 80%, primarily to albumin.
Metabolism: Extensively metabolized in the liver via oxidative demethylation and deamination. The primary metabolic pathway involves CYP2D6, with minor contributions from CYP1A2 and CYP2C19. Neither fluvoxamine nor its metabolites have significant pharmacologic activity. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A4 and CYP2C9. Fluvoxamine has minimal effect on CYP2D6.
Excretion: Eliminated primarily in urine as metabolites. The elimination half-life is approximately 15 to 20 hours in adults, supporting once or twice-daily dosing. Steady-state concentrations are achieved in 10 to 14 days. Non-linear pharmacokinetics may occur at higher doses.
Special populations: Elderly patients and those with hepatic impairment may require dose adjustments due to reduced clearance. Renal impairment does not significantly affect pharmacokinetics.
Adverse effects
Common adverse effects
- Gastrointestinal: Nausea (40%), dyspepsia, diarrhea, anorexia, vomiting — nausea is typically dose-related and may improve with continued use
- Central nervous system: Somnolence (22%), insomnia, dizziness, headache, asthenia, nervousness, tremor
- Sexual dysfunction: Delayed ejaculation, anorgasmia, decreased libido — occurs in 20-30% of patients
- Other: Dry mouth, sweating, palpitations
Serious adverse effects
- Serotonin syndrome — life-threatening condition characterized by mental status changes, autonomic instability, and neuromuscular abnormalities; risk increased with concomitant use of other serotonergic agents
- Suicidal ideation — increased risk in children, adolescents, and young adults (under 24 years) during initial treatment; black box warning mandates close monitoring
- Bleeding — SSRIs impair platelet aggregation; increased risk of gastrointestinal or other bleeding, particularly with concurrent NSAIDs, aspirin, or anticoagulants
- Hyponatremia/SIADH — more common in elderly patients; presents with confusion, weakness, seizures
- Mania/hypomania induction — risk in patients with undiagnosed bipolar disorder
- QT prolongation — dose-dependent; rare at therapeutic doses
- Withdrawal syndrome — abrupt discontinuation may cause dizziness, nausea, sensory disturbances, anxiety; taper gradually
Pregnancy and lactation
Fluvoxamine is FDA pregnancy category C. Third-trimester exposure may cause neonatal adaptation syndrome (jitteriness, respiratory distress, hypotonia). Weigh risks versus benefits. Fluvoxamine is excreted in breast milk; use caution during lactation.
Contraindications and warnings
Absolute contraindications:
- Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI — risk of serotonin syndrome
- Concomitant use with pimozide, tizanidine, or alosetron — fluvoxamine significantly increases levels of these drugs via CYP inhibition, causing serious toxicity
- Known hypersensitivity to fluvoxamine
Warnings and precautions:
- Suicidality: Increased risk in pediatric and young adult patients; monitor closely, especially during initial weeks and dose changes
- Bipolar disorder screening: May precipitate manic episode; screen for bipolar disorder before initiating
- Seizure disorder: Use with caution; SSRIs may lower seizure threshold
- Hepatic impairment: Reduced clearance; consider lower initial doses and slower titration
- Angle-closure glaucoma: Pupillary dilation may trigger angle closure in susceptible individuals
- Bleeding risk: Use caution with anticoagulants, antiplatelet agents, or NSAIDs
- Discontinuation syndrome: Taper gradually; avoid abrupt cessation
- Activation of mania: Monitor for mood changes in patients with risk factors for bipolar disorder
Drug interactions
Fluvoxamine has high potential for clinically significant drug interactions due to potent CYP450 enzyme inhibition.
Critical interactions (contraindicated)
- MAOIs (phenelzine, tranylcypromine, linezolid, methylene blue) — risk of serotonin syndrome; 14-day washout required
- Pimozide — fluvoxamine inhibits CYP3A4/CYP1A2, increasing pimozide levels and QT prolongation risk
- Tizanidine — CYP1A2 inhibition causes severe hypotension and sedation
- Alosetron — CYP1A2 inhibition increases alosetron levels; constipation and ischemic colitis risk
Major interactions requiring monitoring or dose adjustment
| Drug/Class | Mechanism | Clinical Effect |
|---|---|---|
| Warfarin | CYP2C9 inhibition | Increased INR and bleeding risk; monitor closely |
| Theophylline | CYP1A2 inhibition | Increased theophylline levels; toxicity (arrhythmias, seizures) |
| Clozapine | CYP1A2 inhibition | Increased clozapine levels; sedation, seizures, agranulocytosis |
| Olanzapine | CYP1A2 inhibition | Increased olanzapine levels; adjust dose |
| Benzodiazepines (alprazolam, diazepam, triazolam) | CYP3A4 inhibition | Increased sedation; reduce benzodiazepine dose |
| TCAs (clomipramine, imipramine) | CYP1A2/2C19 inhibition | Increased TCA levels; monitor for toxicity |
| Beta-blockers (propranolol) | CYP1A2 inhibition | Increased beta-blocker effect; bradycardia, hypotension |
| Tramadol, meperidine | Serotonergic activity | Risk of serotonin syndrome |
| NSAIDs, aspirin | Platelet dysfunction | Increased bleeding risk |
Other serotonergic agents
Combinations with SSRIs, SNRIs, triptans, St. John's wort, dextromethorphan, or linezolid increase serotonin syndrome risk. Use caution and monitor for symptoms (agitation, hyperthermia, hyperreflexia, clonus).
Clinical pearls
- First-line for OCD in children: Fluvoxamine is FDA-approved for OCD in children aged 8 and older, making it a valuable option in pediatric psychiatry alongside sertraline and fluoxetine.
- Most potent CYP1A2 inhibitor among SSRIs: This makes drug interactions particularly problematic. Always check for drugs metabolized by CYP1A2 (theophylline, clozapine, olanzapine, duloxetine) before prescribing. Minimal effect on CYP2D6 distinguishes it from fluoxetine and paroxetine.
- Sigma-1 receptor activity: Emerging research suggests sigma-1 agonism may have anti-inflammatory effects. This mechanism has generated interest in repurposing fluvoxamine for COVID-19 and other inflammatory conditions, though evidence remains investigational.
- Higher discontinuation rate than other SSRIs: Nausea and somnolence cause more treatment discontinuation compared to fluoxetine or sertraline. Starting at low doses and slow titration can improve tolerability.
- Consider evening dosing: Due to sedating effects in many patients, evening administration may improve tolerability and adherence.
- Smoking affects levels: Cigarette smoking induces CYP1A2, potentially reducing fluvoxamine levels. Higher doses may be needed in smokers; monitor for clinical response.
- Extended-release formulation: Available for social anxiety disorder; may improve tolerability by reducing peak-related adverse effects like nausea.
- Therapeutic drug monitoring: Generally not required, but may be useful in treatment-resistant cases, suspected non-adherence, or to assess drug interactions.
- Washout periods: When switching from fluvoxamine to an MAOI, wait at least 14 days. When switching from fluoxetine to fluvoxamine, consider the long half-life of fluoxetine and its active metabolite.
- Black box warning: Like all antidepressants, carries a warning for increased suicidal thinking and behavior in children, adolescents, and young adults. Document risk-benefit discussion and monitoring plan.
Practice questions
1. A 35-year-old man with obsessive-compulsive disorder is started on fluvoxamine. Three weeks later, he develops agitation, diaphoresis, hyperreflexia, and a temperature of 39.2°C (102.6°F). He reports taking an over-the-counter cold medication containing dextromethorphan. Which of the following best explains his presentation?
2. A 28-year-old woman with OCD is taking fluvoxamine 150 mg daily with good symptom control. She now presents with asthma exacerbation requiring theophylline. Two days after starting theophylline, she develops nausea, vomiting, palpitations, and a seizure. Her theophylline level is 35 mcg/mL (therapeutic range 10-20 mcg/mL). What is the most likely cause?
3. A 10-year-old boy with OCD begins treatment with fluvoxamine. His parents report significant improvement in obsessions and compulsions after 6 weeks. However, they are concerned because he seems more irritable and has made comments about not wanting to live. What is the most appropriate next step in management?
Frequently asked questions
How does fluvoxamine work?
Fluvoxamine works by selectively inhibiting the reuptake of serotonin at presynaptic neurons, increasing serotonin availability in the synaptic cleft. Unlike other SSRIs, it also acts as a potent agonist at sigma-1 receptors, which may contribute to anti-inflammatory effects. This dual mechanism increases serotonergic neurotransmission in brain regions involved in mood and anxiety regulation, particularly beneficial in obsessive-compulsive disorder.
What are the side effects of fluvoxamine?
Common side effects include nausea (affecting up to 40% of patients), somnolence, insomnia, dizziness, headache, and sexual dysfunction such as delayed ejaculation or anorgasmia. Serious but rare adverse effects include serotonin syndrome (especially with other serotonergic drugs), increased suicidal ideation in young patients, hyponatremia (particularly in elderly), bleeding complications, and withdrawal syndrome if stopped abruptly. Nausea often improves with continued use or evening dosing.
Is fluvoxamine a controlled substance?
No, fluvoxamine is not a controlled substance. It is a prescription-only medication classified as an SSRI antidepressant with no potential for abuse or dependence. However, abrupt discontinuation can cause withdrawal symptoms such as dizziness, nausea, and sensory disturbances, so it should be tapered gradually under medical supervision when discontinuing treatment.
Fluvoxamine vs sertraline — what is the difference?
Both are SSRIs used for OCD and depression, but fluvoxamine is a more potent CYP1A2 and CYP2C19 inhibitor, leading to more drug interactions. Fluvoxamine uniquely has sigma-1 receptor agonist activity and causes more nausea and somnolence, while sertraline has a broader FDA indication profile including PTSD and panic disorder. Sertraline is generally better tolerated and more commonly prescribed, whereas fluvoxamine may be preferred for treatment-resistant OCD or when sigma-1 activity is therapeutically desirable.
Can fluvoxamine be used during pregnancy?
Fluvoxamine is FDA pregnancy category C, meaning risk cannot be ruled out. Third-trimester exposure may cause neonatal adaptation syndrome with symptoms like jitteriness, respiratory distress, and feeding difficulties. The decision to use fluvoxamine during pregnancy requires careful risk-benefit assessment, weighing maternal mental health needs against potential fetal risks. If possible, non-pharmacologic interventions should be optimized first, and if medication is necessary, the lowest effective dose should be used with close monitoring.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AB08
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.